{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"051-569-601-830-373","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"051-569-601-830-373","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10771,"type":"PATENT","title":"University of Southern California - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8387,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8241,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
contacting the MEF2 with a small molecule interfacial inhibitor,\n
wherein said interfacial inhibitor is a compound having a formula of\n\nand\n
whereby said interfacial inhibitor modulates the MEF2's function by disrupting the interactions between the MEF2 and a functional binding partner at the MEF2 binding site."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said MEF2 is MEF2A."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said MEF2 is MEF2B."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said MEF2 is MEF2C."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said MEF2 is MEF2D."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["A method of modulating myocyte enhancer factor-2 functions in a subject suffering from a disease related to transcription factor dysregulation, comprising:\n
administering an interfacial inhibitor to said subject,\n
wherein said transcription factor dysregulation is a dysregulation of a transcription factor selected from a group consisting of MEF2A, MEF2B, MEF2C, and MEF2D, or combinations thereof, and,\n
wherein said interfacial inhibitor is a compound having a formula of"],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein said transcription factor dysregulation is a dysregulation of MEF2A."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein said transcription factor dysregulation is a dysregulation of MEF2B."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein said disease is one selected from transplant rejection, inflammation, autoimmune diseases, neurodegenerative diseases, cancer, and cardiovascular disease."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein said transcription factor dysregulation is a dysregulation of MEF2C."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein said transcription factor dysregulation is a dysregulation of MEF2D."],"number":11,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}